Key clinical outcome parameters over the 2-year follow-up (clinical outcome analysis population).
| Time Relative to Start of Tacrolimus Treatment | ||||||
|---|---|---|---|---|---|---|
| Day 0 | Month 1 | Month 3 | Month 6 | Month 12 | Month 24 | |
| No. of patients | 169 | 168 | 148 | 142 | 131 | 108 |
| %FVC | ||||||
| N | 114 | 52 | 24 | 36 | 42 | 18 |
| Mean ± SD | 78.0 ± 19.2 | 77.6 ± 21.2 | 81.3 ± 17.2 | 85.0 ± 15.9 | 88.8 ± 23.2 | 92.7 ± 17.2 |
| %DLCO | ||||||
| N | 56 | 26 | 12 | 20 | 20 | 10 |
| Mean ± SD | 70.0 ± 31.9 | 77.0 ± 41.5 | 86.9 ± 45.0 | 72.7± 28.7 | 69.9 ± 22.1 | 66.5 ± 14.9 |
| PaO2, mmHg | ||||||
| N | 100 | 41 | 18 | 22 | 15 | 6 |
| Mean ± SD | 83.5 ± 16.5 | 86.0 ± 15.9 | 88.2 ± 18.4 | 88.8 ± 15.4 | 88.1 ± 13.3 | 87.4 ± 10.4 |
| AaDO2 mmHg | ||||||
| N | 63 | 28 | 10 | 14 | 12 | 4 |
| Mean ± SD | 22.0 ± 18.7 | 19.1 ± 18.8 | 19.7 ± 26.4 | 20.1 ± 25.5 | 14.2 ± 11.5 | 19.6 ± 12.8 |
| Serum ferritin, ng/mL | ||||||
| N | 118 | 78 | 63 | 61 | 62 | 43 |
| Mean ± SD | 371.0 ± 506.6 | 428.5 ± 572.0 | 258.3 ± 397.6 | 146.4 ± 278.4 | 95.6 ± 117.9 | 75.5 ± 72.8 |
| Serum KL-6, U/mL | ||||||
| N | 154 | 124 | 118 | 112 | 107 | 85 |
| Mean ± SD | 1203.2 ± 915.2 | 1135.7 ± 901.7 | 867.7 ± 802.1 | 882.9 ± 1187.5 | 817.2 ± 771.6 | 627.2 ± 580.6 |
| Serum SP-D, ng/mL | ||||||
| N | 80 | 54 | 44 | 38 | 42 | 27 |
| Mean ± SD | 197.7 ± 234.2 | 115.6 ± 78.9 | 122.5 ± 96.4 | 137.6 ± 132.0 | 108.1 ± 102.3 | 73.7 ± 40.5 |
AaDO2: alveolar-arterial oxygen gradient; %DLCO: percent diffusing capacity for carbon monoxide; %FVC: percent forced vital capacity; KL-6: Krebs von den Lungen 6; n: no. of patients with available data; PaO2: partial pressure of arterial oxygen; SP-D: surfactant protein D.